Introduction
============

Experimental autoimmune encephalomyelitis (EAE), a well-established animal model that recapitulates many clinical and pathophysiological aspects of multiple sclerosis (MS, Baranzini et al., [@B5]) is a T-cell-mediated inflammatory demyelinating disease of the central nervous system (CNS). Like MS, EAE is physiologically characterized by disturbed axonal conduction leading to motor and sensory impairment. Pathological findings in both MS and EAE include infiltration of activated peripheral inflammatory cells into the CNS, loss of myelin and oligodendrocytes, edema, and axonal damage. Astrocytic hypertrophy and astrogliotic scarring are also prominent features of both MS and EAE, and these changes in astrocytes may contribute to conditions that lead to lasting axonal damage, oligodendrocytic loss, and insufficient or absent remyelination. Adoptive transfer (AT-) EAE is induced by injecting myelin antigen-sensitized T-cells obtained from previously immunized syngeneic donor animals. Although more laborious, this form of EAE has a highly synchronous onset and disease course (Mokhtarian et al., [@B39]; Pitt et al., [@B42]). In AT-EAE, myelin basic protein reactive T-cells initiate an immune attack against CNS myelin, characterized by cytokine production and cell death.

There is a rich literature regarding gene expression changes both during normal development and differentiation of myelinating cells (e.g., D\'Antonio et al., [@B13]; Garbay et al., [@B21]; Gokhan et al., [@B22]; Jiang et al., [@B30]) and also the changes that occur acutely (within a day), delayed (within a week), and chronically (several weeks and longer thereafter) following spinal cord (SC) injury (e.g., Carmel et al., [@B11]; Di Giovanni et al., [@B15], see also comprehensive overview in Bareyre and Schwab, [@B6]). Genomic effects of SC injury have also been compared with other conditions related to CNS demyelinating disease such as MS (e.g., Lock et al., [@B36]; Lock and Heller, [@B35]) and mouse-EAE (e.g., Matejuk et al., [@B38]; Xu et al., [@B51]). Moreover, several studies have shown altered expression of genes responsible for myelination in a variety of CNS pathologies (e.g., Haroutunian et al., [@B23]; Kumar et al., [@B34]).

This report extends the analysis of our previously published cDNA microarray study (Brand-Schieber et al., [@B8]) in which we compared the transcriptomes of SC from female syngeneic, age-matched control and AT-EAE SJL/J mice at the peak of clinical disability (clinical index 4 = hind- and front-limb paralysis). The disease was induced by injecting MBP-primed immune cells into syngeneic recipients. We reported that, compared to healthy controls, SC of AT-EAE mice at the peak of disability displayed axonal dystrophy, extensive infiltration of the lumbar ventral white matter with CD11β-immunoreactive monocytes, and a threefold decrease in mRNA encoding the gap junction protein connexin43 (Gja1, connexin43, Cx43).

A subset of 3776 distinct genes with known protein products whose expression levels were adequately quantified in all arrays and averaged for all quantifiable spots probing the same gene, was selected for further analysis reported in this paper. In order to test the hypothesis that coordinated expression with Cx43 might account for some of the observed altered patterns of gene expression, we have compared the coordination profile of Gja1 to those of the immune response and myelination genes.

Materials and Methods {#s1}
=====================

Data set
--------

Briefly, 60 μg total RNA, extracted in trizol from each set of two SC of control (C) and AT-EAE (E) mice was reverse transcribed into cDNA using fluorescent dUTPs \[Cy3-dUTP (green, g) or Cy5-dUTP (red, r)\]. The labeled cDNAs were hybridized overnight at 50°C with four 27 k cDNA microarrays produced by the Microarray Facility of the Albert Einstein College of Medicine (<http://129.98.70.229>) in the combinations: C1(r)C2(g), C3(r)C4(g), E1(r)E2(g), E3(r)E4(g) ("multiple yellow" strategy, see Iacobas et al., [@B26]). The images were acquired and primarily analyzed with GenePix™ Pro 4.1 software ([www.axon.com](www.axon.com)) then normalized according to our in-house developed algorithm. The input data for subsequent analyses were the ratios between the normalized net red/green fluorescence of that spot and the average total net red/green fluorescence of all valid spots in the slide.

The microarray study was performed according to the standards of the Microarray Gene Expression Data Society (MGED) and data complying with the "Minimum Information About Microarray Experiments" (MIAME, Brazma et al., [@B9]) have been deposited in the National Center for Biotechnology Information Gene Expression Omnibus database (<http://www.ncbi.nlm.nih.gov/geo>) as series GSE2446.

Detection of significant regulation
-----------------------------------

We considered a gene as significantly regulated in AT-EAE SC compared to control if the absolute fold change \>1.5× and the *p*-value of the heteroscedastic *t*-test (two-sample unequal variance) applied to the means of the background subtracted normalized fluorescence values in the four biological replicas of the compared transcriptomes was \<0.05. Following previously published procedures (Iacobas et al., [@B28]; Iacobas et al., [@B29]), we have also tested whether large groups of genes sharing same chromosomal location or encoding functionally similar proteins (hereafter termed cohorts) exhibit specific interactions that might regulate and/or perturb the cohort expression profile. Thus, a gene cohort was considered as significantly *regulated* if the average expression level of the composing genes was changed by factor larger than 1.5 and the *p*-value with the Bonferroni adjustment applied to multiple comparisons (Draghici, [@B17]; Iacobas et al., [@B25]; Stekel, [@B49]) was less than 0.05. The expression of a gene cohort was considered as significantly *perturbed* if the standard deviation of the fold changes within that group exceeded 1.5. High standard deviation is interpreted as indicating that the proportions of transcript abundances within the cohort were considerably altered, thereby potentially introducing "bottlenecks" in pathway dynamics by perturbed transcriptomic "stoichiometry" (Iacobas et al., [@B28]; Iacobas et al., [@B29]) which may also change the probability distribution of their outcomes. As in previous papers (Iacobas et al., [@B25]; Iacobas et al., [@B28]; Iacobas et al., [@B29]), the genes were again classified in the following functional cohorts: CSD, Cell cycle, shape, differentiation, death; CYT, cytoskeleton; ENE, energy metabolism; JAE, cell junction, adhesion, extracellular matrix; RNA, RNA processing; SIG, cell signaling; TIC, transport of small molecules and ions into or out of the cells; TRA, transcription; TWC, transport of ions/molecules within the cells; UNK, function not yet assigned.

Variability of transcript abundance and TRA control
---------------------------------------------------

The relative estimated (TRA) variability (REV) and the gene expression stability (GES) of both control and experimental specimens were computed as previously described (Iacobas et al., [@B24]). Since basic transcriptional mechanisms are expected to be similar in a homogeneous set of mice, whereas the local conditions may differ from mouse to mouse, lower REV values are interpreted as indicating lower sensitivity to the local conditions, most probably resulting from increased TRA control, while higher REV values indicate reduced TRA control. Therefore, GES scores reveal the priorities of control over the transcript abundance, with GES = 100 indicating the most stably expressed gene (highest priority in transcript abundance control) and GES = (100/number of quantified genes) the least controlled gene. We organized a database containing the REV and GES values in both conditions and identified the genes for which the system preserved or significantly changed the priorities of TRA control in AT-EAE mice. Both analyses of expression variability and TRA control were extended to the cohorts of genes to test whether the average variability of the cohort was significantly changed in AT-EAE, and whether patterns of hierarchy in expression control among cohorts (significantly different average GES values) were altered in AT-EAE.

TRA coordination
----------------

In order to gain insight into whether expression of individual genes is linked to each other so that the protein amounts would respect the "stoichiometry" of the biochemical reactions, we performed analysis of TRA coordination using the pair-wise Pearson correlation coefficient between sets of expression levels in biological replicas (procedure in Iacobas et al., [@B25]) of both individual genes and gene cohorts to detect specific interactions that may be responsible for perturbation of functional pathways induced by the AT-EAE. At 5% statistical significance, two genes were considered as *synergistically* expressed if the Pearson correlation coefficient ρ~*ij*~ \> 0.9 , *antagonistically* expressed if ρ~*ij*~ \> −0.9, and *independently* expressed if \|ρ~*ij*~\| \> 0.05. For each gene, we determined the *synergome, antagome*, and *exclusome* (i.e., sets of synergistically, antagonistically, or independently expressed partners of a given gene), as well as the *coordination profile* (i.e., the set of the correlation coefficients between expression levels of that gene and each other gene in the biological replicas). Together, the synergome and the antagome of a gene forms its *expressome*. From the point of view that genes whose protein products work together in functional pathways should be coordinately expressed (Iacobas et al., [@B29]), the expressome of a gene indicates the extent of the transcriptomic network related to that gene, while its exclusome indicates the delimitations of this network with respect to other networks. Finally, we compared the coordination profiles of selected genes by computing their overlap (OVL), an indicator ranging from −100 to 100% (Iacobas et al., [@B29]), with high positive values indicating likeness, high negative values opposition, and values close to zero indicating neutrality of the coordination profiles. We termed the gene pairs with OVL \> 80 or OVL \< −80 as "see-saw" partners (Iacobas et al., [@B28]).

Results
=======

Expression regulation
---------------------

As previously reported (Brand-Schieber et al., [@B8]), we found 1433 regulated genes, encompassing all functional classes and located on all chromosomes, thereby indicating a high degree of complexity of the transcriptomic alterations induced by AT-EAE. Affected pathways were identified using GenMapp and MappFinder database searches ([www.genemapp.org](www.genemapp.org); Dahlquist et al., [@B12]; Doniger et al., [@B16]). High up-regulated genes were associated with immune and defense response, moderate up-regulated genes were associated with the proinflammatory response, antigen presentation and processing, immune cell migration, and endosome transport. Low (but still significant) up-regulation included genes related to cholesterol metabolism and cytokine biosynthesis. As antigen presentation and cytokine biosynthesis are components of the immune response, our analysis reveals that these related pathways are up-regulated to a major extent in EAE. Most prominently down-regulated GO categories included heterochromatin, acid phosphatase, cytoplasm organization and biogenesis, mitochondrial inner membrane presequence translocase, regulation of coagulation and chemokine, and cytokine-mediated signaling (zinc finger CCCH-type containing 15, Zc3h15 and suppressor of cytokine signaling 5, Socs5).

We found that no single cohort of genes (open bars in Figures [1](#F1){ref-type="fig"}A and [1](#F1){ref-type="fig"}B) with regard to chromosomal location or function of the encoded protein was entirely regulated unidirectionally, up- and down-regulations of individual genes being roughly balanced within each cohort. An example is shown in Figure [1](#F1){ref-type="fig"}C for part of the subcategory JAE. However, this balance did not extend to the subcohorts: for example, the expression levels of 54 of 56 significantly regulated genes (96%) related to immune response (part of the JAE cohort, see Table [1](#T1){ref-type="table"}) showed significant increases, with histocompatibility 2 class II antigen A alpha (H2-Aa) exhibiting the highest fold change (26.4×). Figure 1**Expression regulation of gene cohorts in AT-EAE mouse spinal cord. A--B**. Log~2~ratios (negative for down-regulation) and standard deviation of expression ratios of gene cohorts sharing the same molecular function (***A***) or chromosomal location (***B***). Note that while the average fold change was less than 1.5 for all cohorts, the standard deviation of the fold change exceeded 1.5. Highest standard deviations were obtained for JAE genes and for those located on chromosome 17. (***C***) Heatmap of the regulated JAE-J genes. C1--C4 = logratios in the four controls, E1--E4 = logratios in the four AT-EAE mice. All logratios were computed with respect to the average expression level in control mice. Red/green/black color indicates up/down/no regulation in the respective set. Note both the reproducibility (green, red, or black color for all four sets of the same condition) and the variability (non-uniform nuance of the color) of the gene expression patterns among the animals of the same condition. Table 1**Regulation of immune response genes in AT-EAE spinal cord**.NameSymbolXpHistocompatibility 2, class II antigen A, alphaH2-Aa26.370.000Complement component 1, q subcomponent, alpha polypeptideC1qa10.030.000Guanylate nucleotide-binding protein 2Gbp29.100.000Complement component 1, q subcomponent, beta polypeptideC1qb8.450.000Proteosome (prosome, macropain) subunit, beta type 9 (large multifunctional protease 2)Psmb98.330.000Histocompatibility 2, class II antigen A, beta 1H2-Ab16.670.000Histocompatibility 2, L regionH2-L6.500.000Histocompatibility 2, K regionH2-K6.330.000Macrophage expressed gene 1Mpeg16.080.000Fc receptor, IgG, low affinity IIIFcgr35.520.001Histocompatibility 2, D region locus 1H2-D15.300.001Chemokine (C--C motif) ligand 9Ccl95.260.001Interferon-induced transmembrane protein 3Ifitm34.460.001B lymphoma Mo-MLV insertion region 1Bmi14.370.001Complement component 3C34.330.005Interferon-induced transmembrane protein 1Ifitm14.230.000Histocompatibility 2, class II, locus DMaH2-DMa4.220.001Interleukin 2 receptor, gamma chainIl2rg3.550.007Tumor necrosis factor, alpha-induced protein 2Tnfaip23.530.000T-cell receptor alpha, variable 22.1Tcra-V22.13.510.000CD44 antigenCd443.240.000Proteosome (prosome, macropain) subunit, beta type 8 (large multifunctional protease 7)Psmb83.240.001LPS-responsive beige-like anchorLrba3.220.002SAM domain and HD domain, 1Samhd13.040.000Interferon regulatory factor 1Irf13.040.000Interleukin 7 receptorIl7r3.030.001Interferon consensus sequence-binding protein 1Icsbp13.010.000B-cell leukemia/lymphoma 2-related protein A1dBcl2a1d2.990.000Complement component factor hCfh2.910.002Interleukin 1 family, member 6Il1f62.830.003Interferon activated gene 203Ifi2032.790.0012′-5′-Oligoadenylate synthetase-like 2Oasl22.710.006SLAM family member 8Slamf82.660.000Fc receptor, IgE, high affinity I, gamma polypeptideFcer1g2.630.005Immunoglobulin superfamily, member 7Igsf72.610.004Interferon-induced transmembrane protein 3-likeIfitm3l2.560.000Immediate early response 3Ier32.550.027Chemokine (C--C motif) ligand 22Ccl222.460.012Histocompatibility 2, Q region locus 7H2-Q72.440.004Histocompatibility 2, complement component factor BH2-Bf2.440.000Small chemokine (C--C motif) ligand 11Ccl112.410.000IL2-inducible T-cell kinaseItk2.390.000Histocompatibility 13H132.380.024Interferon regulatory factor 6Irf62.300.001Proteasome (prosome, macropain) 28 subunit, alphaPsme12.270.003CD47 antigen (Rh-related antigen, integrin-associated signal transducer)Cd472.220.000Chemokine-like factor super family 3Cklfsf32.170.002Interleukin 11 receptor, alpha chain 1Il11ra12.170.000ICOS ligandIcosl2.070.000T-complex-associated testis expressed 3Tcte32.070.000CD1d1 antigenCd1d12.010.001Chemokine (C motif) ligand 1Xcl12.000.006Histocompatibility 2, class II antigen E betaH2-Eb11.780.042Ia-associated invariant chainIi1.760.023Immunoglobulin superfamily, member 8Igsf8−2.200.000Integrin alpha FG-GAP repeat containing 1Itfg1−2.280.000*X, expression ratio (negative for down-regulation) in AT-EAE with respect to control; p, p-value*.

Similarity of the regulomes of AT-EAE SC and Cx43 null brain
------------------------------------------------------------

Since Cx43 was down-regulated in AT-EAE SC by about threefold, we checked whether this alteration of Cx43 expression had similar effects on other genes as observed in Cx43 null brain (Iacobas et al., [@B25]), where significantly regulated genes were also located on all chromosomes and encoded proteins of all major functional categories, extending beyond those that might be expected to depend on junctional communication. Indeed, we found substantial OVL between the regulomes of AT-EAE SC and that of Cx43 null brain with respect to their controls (part of which are listed in Table [2](#T2){ref-type="table"}), with 84% of the 585 significantly altered genes in both samples exhibiting the same type of regulation.

###### 

**Representative examples of significantly regulated JAE genes in EAE spinal cord (EAE) and in Cx43 null brain (BR)**.

  GB ACC     Name                                                                 Symbol          EAE     BR
  ---------- -------------------------------------------------------------------- --------------- ------- -------
  AA266651   Afamin                                                               Afm             3.29    1.64
  AW552701   Amyloid beta (A4) precursor protein                                  App             −3.00   −5.47
  AA544881   Attractin                                                            Atrn            1.65    1.53
  AU044759   Cadherin 22                                                          Cdh22           2.51    1.68
  AW537209   Calsyntenin 1                                                        Clstn1          −2.26   −2.24
  AI573427   Catenin beta                                                         Catnb           −2.26   −2.79
  AA154812   Claudin 10                                                           Cldn10          1.96    1.59
  AI425965   Contactin 1                                                          Cntn1           −1.87   −1.77
  AU040950   Ependymin 2                                                          Epdm2-pending   −4.13   −1.69
  W58845     Fc receptor, IgE, high affinity I, gamma polypeptide                 Fcer1g          2.63    1.52
  AA277329   Histocompatibility 2, class II antigen E beta                        H2-Eb1          1.78    1.50
  AA061908   Integrin alpha M                                                     Itgam           3.52    1.59
  AW545236   Mitochondrial ribosomal protein L28                                  Mrpl28          −1.72   −1.92
  C79334     Musculin                                                             Msc             2.01    1.64
  AW537800   N-ethylmaleimide sensitive fusion protein attachment protein alpha   Napa            −4.17   −1.82
  AI323974   Neuropilin                                                           Nrp             1.77    1.64
  C85793     Putative neuronal cell adhesion molecule                             Punc            1.90    1.60
  AI414315   Rhomboid, veinlet-like 4 (*Drosophila*)                              Rhbdl4          1.51    1.59
  AI327207   Tenascin C                                                           Tnc             2.52    1.78
  AA249976   Xeroderma pigmentosum, complementation group C                       Xpc             1.64    1.58

*Values in right-most columns indicate fold change (negative for down-regulation). Note that although fold changes differ, all listed genes were regulated in the same direction in both experimental groups*.

Regulation of expression variability
------------------------------------

Figure [1](#F1){ref-type="fig"}C illustrates the variability of gene expression among animals of the same condition (note the non-uniform color nuances in the heatmap representation). We found that the overall TRA variability increased from 42.5% in the control mice to 49.7% in the AT-EAE mice, indicating a significant (*p* \< 0.0001) loss of the overall TRA control in the diseased mice. This observation of overall increased variability in EAE mice compared to controls was robust for all functional cohorts (Figure [2](#F2){ref-type="fig"}A) and all chromosomal locations (Figure [2](#F2){ref-type="fig"}B) with a slight bias toward CYT genes, perhaps reflecting the ongoing alterations in the tissue of these animals. However, both control and EAE specimens had uniform control stringencies among functional categories (Figure [2](#F2){ref-type="fig"}C) and chromosomal locations (not shown) as indicated by the roughly uniform distributions of the GES scores. Figure 2**Regulation of the mean relative expression variability (REV) of gene cohorts sharing the same molecular function (A) or chromosomal location (B) in spinal cords of AT-EAE mice compared to control mice**. (***C***) Average gene expression stability (GES) of functional gene cohorts. Note the uniformity of the two REV distributions both among functional classes: REV(C) = (42.9 ± 2.3)%, REV(E) = (50.2 ± 2.3)% and among chromosomes: REV(C) = (42.5 ± 2.1)%, REV(E) = (49.7 ± 2.3)% and that all functional and chromosomal cohorts became less stably expressed (higher REV) in AT-EAE mice, with the highest increments in the transport into cell (23.8%) and chromosome 13 (34.1%). Cytoskeleton genes were the most unstably expressed in both conditions. Observe the quasi-uniform distribution of GES values among functional categories for both control and AT-EAE specimens.

Table [3](#T3){ref-type="table"} presents examples of very stably and very unstably expressed genes in the control mice that significantly preserved or changed their stability classes in AT-EAE mice.

###### 

**Examples of genes that conserved (SS and UU in STAB column) or significantly changed (SU and US in STAB column) their stability or instability in AT-EAE spinal cord with respect to controls**.

  STAB   Name                                                                                 Symbol          CHR   FUNC   GES-C   GES-E   REG
  ------ ------------------------------------------------------------------------------------ --------------- ----- ------ ------- ------- -----
  SS     Phosphofructokinase, platelet                                                        Pfkp            13    ENE    98.04   98.17   ↓
  SS     Burkitt lymphoma receptor 1                                                          Blr1            9     SIG    98.62   98.78   ↑
  SS     Ethanol induced 2                                                                    Etohi2          15    UNK    96.13   95.74   ↓
  SS     Cadherin 2                                                                           Cdh2            18    JAE    99.21   98.57   ↓
  SS     Ephrin A5                                                                            Efna5           17    JAE    97.38   98.04   ↓
  SS     START domain containing 7                                                            Stard7          2     UNK    95.23   94.17   ↓
  SS     Bmi1 upstream gene                                                                   Bup             2     UNK    96.64   98.07   
  SS     Gene trap locus 3                                                                    Gtl3            8     TRA    98.44   99.92   ↓
  SS     Muscleblind-like 3 (*Drosophila*)                                                    Mbnl3           X     CSD    96.72   98.25   ↓
  SS     Coatomer protein complex, subunit epsilon                                            Cope            8     TWC    95.47   97.25   
  SS     Translation factor sui1 homolog                                                      Gc20-pending    9     RNA    99.31   97.35   ↓
  SS     DiGeorge syndrome critical region gene 2                                             Dgcr2           16    TWC    96.61   98.81   
  SS     Ribosomal protein L13                                                                Rpl13           8     RNA    95.66   99.13   ↓
  SS     High mobility group box 1                                                            Hmgb1           5     TRA    97.19   93.59   ↓
  SS     ADP-ribosylation factor-like 4                                                       Arl4            12    SIG    98.23   94.44   ↑
  SU     Ornithine aminotransferase                                                           Oat             7     ENE    96.40   8.85    
  SU     UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 4   Galnt4          10    ENE    88.29   0.45    
  SU     Histone cell cycle regulation defective interacting protein 5                        Hirip5          6     UNK    93.19   5.11    ↓
  SU     Chloride intracellular channel 1                                                     Clic1           17    TIC    99.87   11.10   
  SU     Interleukin-1 receptor-associated kinase 1                                           Irak1           X     SIG    88.90   0.05    
  SU     Tubulin, alpha 2                                                                     Tuba2           15    CYT    97.83   8.92    
  SU     RE1-silencing transcription factor                                                   Rest            5     TRA    90.84   1.72    
  SU     Acetyl-coenzyme A acyltransferase 1                                                  Acaa1           9     ENE    99.97   10.70   
  SU     Src homology 2 domain-containing transforming protein D                              Shd             17    SIG    95.60   6.04    
  SU     T-complex-associated testis expressed 1                                              Tcte1           17    TWC    90.86   1.22    
  SU     Coatomer protein complex, subunit zeta 1                                             Copz1           15    TWC    95.42   5.75    
  SU     Sorting nexin 4                                                                      Snx4            16    TWC    94.65   4.69    
  SU     Cleavage and polyadenylation specificity factor 1                                    Cpsf1           15    RNA    95.21   4.10    
  SU     Cystathionase (cystathionine gamma-lyase)                                            Cth             3     ENE    92.24   0.95    
  SU     Chronic myelogenous leukemia tumor antigen 66                                        Cml66-pending   15    JAE    94.33   2.97    
  US     RPEL repeat containing 1                                                             Rpel1           13    UNK    0.69    99.76   
  US     F-box and WD-40 domain protein 5                                                     Fbxw5           2     UNK    1.69    99.47   
  US     Ankyrin repeat domain 10                                                             Ankrd10         8     TRA    4.42    98.28   ↑
  US     Chromobox homolog 3 (*Drosophila* HP1 gamma)                                         Cbx3            6     TRA    3.68    96.03   
  US     DEAD (Asp-Glu-Ala-Asp) box polypeptide 24                                            Ddx24           12    TRA    4.40    96.00   
  US     Protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), alpha isoform     Ppp2r2a         14    SIG    2.49    95.37   
  US     Myotubularin-related protein 1                                                       Mtmr1           X     CYT    1.03    95.26   
  US     GNAS (guanine nucleotide-binding protein, alpha stimulating) complex locus           Gnas            2     SIG    3.20    94.84   
  US     Coatomer protein complex, subunit gamma 2, antisense 2                               Copg2as2        6     TWC    1.06    92.43   
  US     Four jointed box 1 (*Drosophila*)                                                    Fjx1            2     UNK    2.15    92.03   
  US     Glycogen synthase kinase 3 beta                                                      Gsk3b           16    SIG    4.05    91.68   
  US     BH3 interacting domain death agonist                                                 Bid             6     CSD    1.38    91.42   
  US     Solute carrier family 14 (urea transprorter), member 1                               Slc14a1         18    TIC    0.56    91.39   
  US     Eukaryotic translation initiation factor 2 alpha kinase 4                            Eif2ak4         2     RNA    3.26    90.84   
  US     Cytochrome b-561                                                                     Cyb561          11    ENE    2.99    90.23   
  UU     Nectin-lke 1                                                                         Necl1-pending   1     UNK    0.21    6.94    
  UU     Neural precursor cell expressed, developmentally down-regulated gene 4               Nedd4           9     ENE    4.98    6.73    
  UU     Brain protein 17                                                                     Brp17           1     UNK    4.82    6.62    
  UU     MAD homolog 1 (*Drosophila*)                                                         Madh1           8     SIG    2.89    5.61    
  UU     Myeloid/lymphoid or mixed-lineage leukemia 5                                         Mll5            5     TRA    0.13    4.93    
  UU     Estrogen receptor 1 (alpha)                                                          Esr1            10    SIG    1.54    4.56    
  UU     Mpv17 transgene, kidney disease mutant                                               Mpv17           5     ENE    1.80    4.50    
  UU     Beta-1,3-glucuronyltransferase 3 (glucuronosyltransferase I)                         B3Gat3          19    ENE    4.29    2.60    
  UU     Ring finger protein 103                                                              Rnf103          6     TRA    3.10    2.38    
  UU     Metastasis suppressor 1                                                              Mtss1           15    CYT    3.15    1.67    
  UU     Sparc/osteonectin, cwcv and kazal-like domains proteoglycan 1                        Spock1          13    JAE    3.73    1.01    
  UU     A disintegrin and metalloproteinase domain 19 (meltrin beta)                         Adam19          11    JAE    2.07    0.72    
  UU     Guanine nucleotide-binding protein, alpha 11                                         Gna11           10    SIG    1.19    0.69    
  UU     Transducin-like enhancer of split 4, E(spl) homolog (*Drosophila*)                   Tle4            19    TRA    0.90    0.64    
  UU     Seri drox m l transferas mitochon                                                    Shmt2           10    ENE    0.29    0.37    

*CHR, chromosome location; FUNC, functional class; GES-C and GES-E are the gene expression stabilities in control C and AT-EAE (E) spinal cord while arrows in the REG column indicate whether the gene was significantly up- or down-regulated in E specimens*.

TRA coordination
----------------

The average gene in control SC was found to be synergistically expressed with 467 genes (i.e., 12.4% of 3776), antagonistically expressed with 401 (10.6 %), and independently expressed with 231 (6.1%). As illustrated in Figure [3](#F3){ref-type="fig"}A, these numbers were not significantly altered in the AT-EAE mice: average synergome size = 436 (11.5%), antagome = 397 (10.6%), and exclusome = 241 (6.4%). However, the networks of genes that were connected to one another were markedly altered, as indicated by the lack of correlation between the control and AT-EAE expressomes and exclusomes. In both conditions, we found remarkably bimodal distributions of coordination frequencies (Figure [3](#F3){ref-type="fig"}B). Figure 3**Transcription coordination**. (***A***) The 95% confidence intervals of the percentages of synergistically (Syn), antagonistically (Ant), and independently (Ind) expressed gene pairs in spinal cord of control (C) and AT-EAE (E) mice. Note that the intervals remained practically unchanged in AT-EAE. (***B***) Histograms of the expression coordinations (SYN + ANT) in control and AT-EAE spinal cord. Note the two modal distributions in both conditions, with two distinct groups of genes: one group in which most genes are coordinately expressed with 4--8% of the other genes and the second group in which most genes are coordinately expressed with 40--44% of the other genes. (***C***) Examples in which percentages of statistically significant coordination partners of myelination genes differed between control and AT-EAE spinal cords. Chk, choline kinase; Fyn, Fyn proto-oncogene; Hmgcr, 3-hydroxy-3-methylglutaryl-coenzyme A reductase; Mal, myelin and lymphocyte protein T-cell differentiation protein; Mpz, myelin protein zero; Nsmaf, neutral sphingomyelinase activation-associated factor; Pdgfra, platelet derived growth factor receptor alpha polypeptide; Pdgfrb, platelet derived growth factor receptor beta polypeptide; Pdgfrl, platelet-derived growth factor receptor-like; Plp, proteolipid protein; Pmp22, peripheral myelin protein; Qk, quaking; Scd1, stearoyl-coenzyme A desaturase 1; Scd2, stearoyl-coenzyme A desaturase 2; Smpd1, sphingomyelin phosphodiesterase 1 acid lysosomal; Smpdl3a, sphingomyelin phosphodiesterase acid-like 3A.

Some genes exhibited very low numbers of coordinated partners as compared to the average gene; for example, T-complex-associated testis expressed 3 (Tcte3) and P2rx3 have expressomes covering only 2.4 and 2.5% of the sampled transcriptome. In contrast, other genes had large numbers of coordinated partners, such as Spastin (Spast) with an expressome of 45.3% of the transcriptome, and ATP synthase H^+^ transporting mitochondrial F1 complex gamma polypeptide 1 (Atp5c1), whose expressome encompassed 45.2% of the transcriptome. A large diversity of coordination degrees was found among the genes involved in myelination. Thus, Pmp22 was coordinately expressed with over 43% of the selection, while Nsmaf was coordinated with only 5% of the selection (Figure [3](#F3){ref-type="fig"}C).

Although coordination of the average gene was not significantly changed in AT-EAE mice, the coordinations within gene cohorts were markedly affected. Thus, the coordination of 13 out of 16 quantified genes related to myelination decreased significantly, while the coordination of stearoyl-coenzyme A desaturases 1 and 2 (Scd1, Scd2) and sphingomyelin phosphodiesterase 1, acid lysosomal (Smpd1) increased significantly.

When the average coordination degree was computed for gene cohorts, we found rather uniform distributions with regard to chromosomal location and functional categories in control as well as in AT-EAE samples (Figures [4A--4D](#F4){ref-type="fig"}), similar to our findings in brain of the nenatal mouse (Iacobas et al., [@B28]). If both coordination and variability of gene expression reflect control mechanisms to promote transcriptome stability, we might expect that these parameters would be mathematically related. Indeed, we found that the coordination decreased exponentially with the expression control (GES), a robust observation for both conditions (Figures [4](#F4){ref-type="fig"}E and [4](#F4){ref-type="fig"}F). Figure 4**Average percentages of synergistically (Syn), antagonistically (Ant), and independently (Ind) expressed gene pairs in functional categories (A and B), chromosomes (C and D) and GES percentiles for control (A, C, E) and AT-EAE (B, D, F) spinal cords**. Note the quasi-uniform distributions of the percentages in functional categories and chromosomal locations in both conditions, the not-significant alteration of the percentages in AT-EAE mice and the inverse exponential relationship between synergistic and antagonistic coordination and expression stability (GES percentile).

Table [4](#T4){ref-type="table"} presents the genes with the largest and the smallest synergomes, antagomes, and exclusomes in control SC and the corresponding values in AT-EAE mice, while Table [5](#T5){ref-type="table"} presents the sizes of the synergomes, antagomes, and exclusomes of the quantified immune response genes in controls.

###### 

**Examples of genes with high (H) and low (L) percentages of synergistic (SYN), antagonistic (ANT), and independent (IND) expression partners within the control (C) spinal cord and the corresponding values for AT-EAE (E) mice**.

  Type    Name                                                                                 Symbol        CHR   FUNC   SYN-C   ANT-C   IND-C   SYN-E   ANT-E   IND-E
  ------- ------------------------------------------------------------------------------------ ------------- ----- ------ ------- ------- ------- ------- ------- -------
  H-SYN   A disintegrin and metalloprotease domain 10                                          Adam10        9     JAE    28.02   16.76   3.18    16.79   16.55   4.53
  H-SYN   Hermansky--Pudlak syndrome 1 homolog (human)                                         Hps1          19    TWC    27.97   16.87   3.31    18.99   18.64   4.10
  H-SYN   Myotubularin-related protein 1                                                       Mtmr1         X     CYT    27.97   17.19   3.39    5.46    1.48    8.10
  H-SYN   Potassium channel tetramerisation domain containing 2                                Kctd2         11    TIC    27.97   17.08   3.50    8.05    4.18    5.88
  H-SYN   Bromodomain containing 3                                                             Brd3          2     TRA    27.94   16.66   3.39    4.77    2.01    14.14
  H-SYN   Carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase     Cad-pendin    5     ENE    27.94   16.98   3.39    17.51   18.30   3.84
  H-SYN   CBF1 interacting corepressor                                                         Cir-pending   2     TRA    27.94   16.90   3.44    14.30   10.99   4.69
  H-SYN   Enoyl-coenzyme A hydratase, short chain, 1, mitochondrial                            Echs1         7     ENE    27.94   16.74   3.20    23.28   15.04   4.08
  H-SYN   Nuclear receptor subfamily 3, group C, member 1                                      Nr3c1         18    CSD    27.94   16.60   3.26    23.54   16.53   4.10
  H-SYN   Nuclear receptor coactivator 1                                                       Ncoa1         12    CSD    27.91   17.16   3.42    8.08    4.90    4.74
  L-SYN   Glucose phosphate isomerase 1                                                        Gpi1          7     ENE    0.85    2.38    21.82   4.40    1.43    16.37
  L-SYN   Exostoses (multiple)-like 3                                                          Extl3         14    CSD    0.87    2.01    16.82   14.88   23.17   4.05
  L-SYN   Phosphoglycerate dehydrogenase like 1                                                Phgdhl1       14    ENE    0.87    2.75    15.89   5.99    10.51   5.16
  L-SYN   Cytotoxic T lymphocyte-associated protein 2 beta                                     Ctla2b        12    JAE    0.90    1.67    25.85   19.12   14.22   3.55
  L-SYN   HLA-B-associated transcript 8                                                        Bat8          17    TRA    0.90    2.38    21.64   17.51   13.06   3.60
  L-SYN   Nuclear factor of kappa light chain gene enhancer in B-cells inhibitor, alpha        Nfkbia        12    TRA    0.90    1.69    25.50   12.39   15.39   4.37
  L-SYN   Phospholipase D3                                                                     Pld3          7     SIG    0.93    2.91    16.18   15.84   16.45   4.74
  L-SYN   Acetyl-coenzyme A acetyltransferase 1                                                Acat1         9     ENE    0.95    2.75    12.24   20.10   17.45   3.84
  L-SYN   Fucosidase, alpha-L-1, tissue                                                        Fuca          4     ENE    0.95    1.88    13.45   18.96   10.30   4.45
  L-SYN   Glyoxalase 1                                                                         Glo1          17    ENE    0.95    2.78    11.81   12.98   21.66   4.16
  H-ANT   Spastic paraplegia 7 homolog (human)                                                 Spg7          8     UNK    17.27   28.05   3.50    14.80   23.09   4.00
  H-ANT   Protein tyrosine phosphatase, non-receptor type 9                                    Ptpn9         9     SIG    17.13   28.02   3.42    1.14    3.87    16.58
  H-ANT   Dehydrogenase/reductase (SDR family) member 1                                        Dhrs1         14    ENE    16.95   27.99   3.58    3.95    8.58    6.09
  H-ANT   Kinesin family member 23                                                             Kif23         9     TWC    16.84   27.97   3.31    16.63   17.32   4.18
  H-ANT   RNA and export factor-binding protein 2                                              Refbp2        1     TRA    16.92   27.97   3.34    16.74   22.70   3.65
  H-ANT   ADP-ribosylation factor 1                                                            Arf1          11    TWC    16.31   27.94   3.23    17.06   23.97   3.73
  H-ANT   Fibroblast growth factor (acidic) intracellular-binding protein                      Fibp          19    CSD    17.16   27.91   3.50    2.78    2.07    6.41
  H-ANT   HECT domain containing 1                                                             Hectd1        12    UNK    17.06   27.91   3.47    2.91    4.48    7.42
  H-ANT   ATP synthase, H+ transporting, mitochondrial F1 complex, gamma polypeptide 1         Atp5c1        2     TWC    17.32   27.89   3.44    16.95   18.03   4.58
  H-ANT   Nuclear RNA export factor 1 homolog (*S. cerevisiae*)                                Nxf1          19    TWC    17.27   27.89   3.55    5.61    3.63    7.63
  L-ANT   B-cell receptor-associated protein 29                                                Bcap29        12    TWC    2.28    0.85    19.94   22.83   13.98   4.32
  L-ANT   Neighbor of Punc E11                                                                 Nope          9     TIC    2.22    0.85    20.15   7.42    5.80    4.95
  L-ANT   v-rel reticuloendotheliosis viral oncogene homolog A (avian)                         Rela          19    TRA    1.83    0.85    17.88   23.73   16.84   4.03
  L-ANT   Fat-specific gene 27                                                                 Fsp27         6     CSD    2.41    0.87    14.43   19.92   10.81   4.21
  L-ANT   Ligand of numb-protein X 2                                                           Lnx2          5     SIG    2.75    0.87    15.86   4.29    6.59    3.34
  L-ANT   ras homolog gene family, member H                                                    Arhh          5     SIG    2.20    0.87    17.74   2.54    0.95    13.59
  L-ANT   CpG-binding protein                                                                  Cgbp-pend     18    TRA    1.85    0.90    23.68   18.51   19.39   4.05
  L-ANT   Hydroxyacid oxidase 1, liver                                                         Hao1          2     ENE    2.30    0.90    18.96   10.17   5.72    5.72
  L-ANT   miRNA containing gene                                                                Mirg          12    UNK    2.04    0.90    24.36   9.24    5.88    4.74
  L-ANT   Sphingosine-1-phosphate phosphatase 1                                                Sgpp1         12    ENE    2.25    0.90    19.33   12.45   10.54   4.69
  H-IND   Anterior gradient 2 (*Xenopus laevis*)                                               Agr2          12    UNK    1.03    1.51    26.11   6.99    3.20    7.73
  H-IND   Argininosuccinate lyase                                                              Asl           5     ENE    1.67    0.93    25.85   7.36    4.98    6.44
  H-IND   Cytotoxic T-lymphocyte-associated protein 2 beta                                     Ctla2b        12    JAE    0.90    1.67    25.85   19.12   14.22   3.55
  H-IND   ATP-binding cassette, sub-family G (WHITE), member 4                                 Abcg4         9     TIC    1.14    1.38    25.74   6.44    10.20   5.03
  H-IND   Sorting nexin 10                                                                     Snx10         6     TWC    1.01    1.67    25.72   16.98   23.83   4.10
  H-IND   myc-induced nuclear antigen                                                          Mina          16    CSD    1.75    1.03    25.48   20.34   10.91   4.16
  H-IND   Acetyl-coenzyme A acyltransferase 2 (mitochondrial 3-oxoacyl-coenzyme A thiolase     Acaa2         18    ENE    1.35    1.30    25.32   17.64   23.57   3.76
  H-IND   Ena-vasodilator stimulated phosphoprotein                                            Evl           12    SIG    1.01    1.77    25.32   8.63    4.45    4.79
  H-IND   Solute carrier family 25 (mitochondrial carrier; ornithine transporter), member 15   Slc25a15      8     TWC    1.59    1.11    25.19   11.10   6.25    5.40
  H-IND   AE-binding protein 2                                                                 Aebp2         6     TRA    1.80    0.95    24.97   1.85    4.82    16.45
  L-IND   Acidic (leucine-rich) nuclear phosphoprotein 32 family, member E                     Anp32e        3     UNK    26.30   13.22   2.83    4.79    1.48    16.31
  L-IND   Fatty acid amide hydrolase                                                           Faah          4     ENE    27.20   14.38   2.83    18.46   9.90    4.56
  L-IND   Meiotic recombination 11 homolog A (*S. cerevisiae*)                                 Mre11a        9     ENE    26.24   13.11   2.83    24.02   16.98   5.48
  L-IND   BCL2-associated athanogene 4                                                         Bag4          8     CSD    25.98   12.95   2.89    15.76   8.18    5.08
  L-IND   KDEL containing protein 1                                                            Kdel1         1     TRA    26.22   13.19   2.89    24.02   16.98   3.34
  L-IND   Nuclear fragile X mental retardation protein interacting protein                     Nufip1        14    TWC    24.55   11.57   2.89    13.16   6.81    5.22
  L-IND   T-box 2                                                                              Tbx2          11    TRA    26.01   12.71   2.89    19.23   20.37   3.42
  L-IND   Disrupted in bipolar disorder 1 homolog (human)                                      Dibd1         9     TRA    27.09   14.27   2.91    9.19    5.27    5.61
  L-IND   Phosphatidylglycerophosphate synthase 1                                              Pgs1-pend     11    UNK    14.19   27.12   2.91    1.11    2.01    7.71
  L-IND   Solute carrier family 4, sodium bicarbonate cotransporter, member 7                  Slc4a7        14    TIC    26.22   13.29   2.91    5.01    2.38    10.67

*CHR, chromosome location; FUNC, primary function performed by the encoded protein*.

###### 

**The extent of the synergomes (SYN), antagomes (ANT), expresomes (EXP = SYN + ANT), and exclusomes (EXC) of the immune response genes in the control spinal cord**.

  Name                                                                                      Symbol       SYN     ANT     EXP     EXC
  ----------------------------------------------------------------------------------------- ------------ ------- ------- ------- -------
  B-cell receptor-associated protein 31                                                     Bcap31       17.46   27.23   44.69   1.91
  Interferon-induced transmembrane protein 3                                                Ifitm3       16.58   27.79   44.37   1.64
  Histocompatibility 2, class II antigen E beta                                             H2-Eb1       27.50   15.84   43.34   1.56
  Chemokine-like factor super family 3                                                      Cklfsf3      27.34   15.52   42.86   1.48
  B-lymphoma Mo-MLV insertion region 1                                                      Bmi1         16.45   25.72   42.17   1.70
  Histocompatibility 13                                                                     H13          24.64   17.35   41.99   1.93
  CD1d1 antigen                                                                             Cd1d1        16.13   24.74   40.87   1.64
  CD44 antigen                                                                              Cd44         16.87   21.91   38.78   2.04
  Proteosome (prosome, macropain) subunit, beta type 8 (large multifunctional protease 7)   Psmb8        23.34   15.18   38.52   1.85
  Cd300D antigen                                                                            Cd300d       16.50   20.13   36.64   2.04
  Chemokine (C--C motif) ligand 22                                                          Ccl22        23.52   10.49   34.01   1.70
  Histocompatibility 2, L region                                                            H2-L         18.07   14.52   32.58   2.12
  B-cell leukemia/lymphoma 2-related protein A1d                                            Bcl2a1d      12.13   20.29   32.42   2.17
  Small chemokine (C--C motif) ligand 11                                                    Ccl11        11.87   19.36   31.23   1.59
  Interferon regulatory factor 6                                                            Irf6         18.57   9.99    28.56   1.91
  Interleukin 2 receptor, gamma chain                                                       Il2rg        19.05   8.77    27.81   1.75
  Histocompatibility 2, class II, locus DMa                                                 H2-DMa       16.72   8.34    25.06   2.01
  Proteosome (prosome, macropain) subunit, beta type 9 (large multifunctional protease 2)   Psmb9        16.72   8.08    24.79   2.09
  Histocompatibility 2, class II antigen A, alpha                                           H2-Aa        12.37   10.62   22.99   1.85
  SAM domain and HD domain, 1                                                               Samhd1       12.13   9.64    21.77   1.83
  LPS-responsive beige-like anchor                                                          Lrba         14.17   7.02    21.19   2.09
  Proteasome (prosome, macropain) 28 subunit, alpha                                         Psme1        9.56    11.15   20.72   1.80
  Fc receptor, IgE, high affinity I, gamma polypeptide                                      Fcer1g       9.99    9.30    19.28   2.86
  Histocompatibility 2, class II antigen A, beta 1                                          H2-Ab1       12.40   5.85    18.25   2.12
  Complement component 1, q subcomponent, alpha polypeptide                                 C1qa         5.06    12.56   17.62   2.04
  Interferon-induced transmembrane protein 3-like                                           Ifitm3l      9.83    6.86    16.69   2.52
  Interferon-induced transmembrane protein 1                                                Ifitm1       4.03    11.36   15.39   1.83
  2′-5′-oligoadenylate synthetase-like 2                                                    Oasl2        10.70   4.03    14.73   2.52
  Chemokine (C--C motif) ligand 9                                                           Ccl9         6.83    5.96    12.79   2.75
  ICOS ligand                                                                               Icosl        6.44    6.15    12.58   2.23
  Interferon activated gene 203                                                             Ifi203       8.53    3.39    11.92   2.25
  Histocompatibility 2, Q region locus 7                                                    H2-Q7        8.03    3.79    11.81   2.28
  Tumor necrosis factor, alpha-induced protein 2                                            Tnfaip2      7.60    3.55    11.15   1.96
  Complement component 1, q subcomponent, beta polypeptide                                  C1qb         7.50    2.70    10.20   2.46
  CD47 antigen (Rh-related antigen, integrin-associated signal transducer)                  Cd47         5.48    4.56    10.04   2.86
  Histocompatibility 2, K1, K region                                                        H2-K1        5.93    3.74    9.67    2.12
  Chemokine (C motif) ligand 1                                                              Xcl1         5.43    2.15    7.58    3.02
  T-cell receptor alpha, variable 22.1                                                      Tcra-V22.1   4.53    2.78    7.31    2.97
  SLAM family member 8                                                                      Slamf8       4.90    2.04    6.94    3.15
  Interleukin 7 receptor                                                                    Il7r         3.50    1.93    5.43    7.26
  Histocompatibility 2, complement component factor B                                       H2-Bf        1.77    3.31    5.09    7.84
  IL2-inducible T-cell kinase                                                               Itk          3.34    1.72    5.06    4.64
  Interferon consensus sequence-binding protein 1                                           Icsbp1       2.70    2.15    4.85    6.78
  Complement component factor h                                                             Cfh          2.83    1.93    4.77    6.91
  Complement component 3                                                                    C3           2.60    2.09    4.69    3.18
  Histocompatibility 2, D region locus 1                                                    H2-D1        2.20    1.72    3.92    4.79
  Interleukin 1 family, member 6                                                            Il1f6        2.75    1.01    3.76    10.68
  Interferon regulatory factor 1                                                            Irf1         2.68    1.09    3.76    8.00
  Interleukin 11 receptor, alpha chain 1                                                    Il11ra1      1.14    2.60    3.74    9.17
  Guanylate nucleotide-binding protein 2                                                    Gbp2         1.88    1.48    3.36    5.32
  Macrophage expressed gene 1                                                               Mpeg1        1.14    1.59    2.73    9.99
  Immediate early response 3                                                                Ier3         1.06    1.59    2.65    11.15
  Fc receptor, IgG, high affinity I                                                         Fcgr3        1.17    1.40    2.57    7.87
  T-complex-associated testis expressed 3                                                   Tcte3        1.01    1.40    2.41    12.29

Table [6](#T6){ref-type="table"} presents examples of genes that preserved or significantly changed the expressome size in AT-EAE SC. Thus, the B-cell receptor-associated protein 31 (Bcap31), that is preferentially associated with the membrane antigen receptor IgD (Adachi et al., [@B1]) maintained its high coordination degree in both conditions, whereas other genes showed substantial alterations in coordinated expression.

###### 

**Examples of genes that preserved (HH and LL) or significantly changed (HL and LH) the coordination (SYN + ANT) degree in AT-EAE (E) spinal cord as compared to controls (C)**.

  Type   Name                                                                                        Symbol        CHR   FUNC   SYN-C   ANT-C   IND-C   SYN-E   ANT-E   IND-E
  ------ ------------------------------------------------------------------------------------------- ------------- ----- ------ ------- ------- ------- ------- ------- -------
  HH     B-cell receptor-associated protein 31                                                       Bcap31        X     TWC    17.45   27.22   3.42    19.25   22.17   3.39
  HH     E4F transcription factor 1                                                                  E4f1          17    TRA    27.04   17.66   3.47    22.46   18.94   3.65
  HH     Ferrochelatase                                                                              Fech          18    ENE    27.78   17.27   3.50    21.98   19.23   3.44
  HH     Fibroblast growth factor receptor 1                                                         Fgfr1         8     CSD    27.28   17.53   3.50    23.73   17.43   3.84
  HH     Gamma-glutamyl carboxylase                                                                  Ggcx          6     ENE    27.89   16.79   3.31    22.80   17.61   3.18
  HH     Golgi apparatus protein 1                                                                   Glg1          8     TWC    27.36   17.24   3.47    23.17   18.19   3.26
  HH     Immediate early response 5                                                                  Ier5          1     CSD    17.24   27.44   3.36    18.22   23.33   3.39
  HH     Mpv17 transgene, kidney disease mutant                                                      Mpv17         5     ENE    27.75   16.84   3.31    24.02   17.32   3.55
  HH     Neural proliferation, differentiation and control gene 1                                    Npdc1         2     UNK    27.86   17.13   3.47    21.61   18.83   3.55
  HH     Nuclear cap-binding protein subunit 2                                                       Ncbp2         16    UNK    27.73   17.27   3.55    23.70   18.06   3.36
  HH     Placental-specific protein 1                                                                Plac1         X     UNK    17.40   27.20   3.50    23.33   18.59   3.20
  HH     Ring finger protein 103                                                                     Rnf103        6     TRA    27.81   17.11   3.58    24.05   17.88   3.44
  HH     SEC61, gamma subunit                                                                        Sec61g        11    TWC    17.40   27.33   3.50    18.06   23.41   3.68
  HH     Transducin-like enhancer of split 4, E(spl) homolog (*Drosophila*)                          Tle4          19    TRA    27.54   17.29   3.58    24.02   17.45   3.10
  HH     Ubiquitination factor E4B, UFD2 homolog (*S. cerevisiae*)                                   Ube4b         4     ENE    27.30   17.29   3.44    21.85   19.07   3.23
  HL     Bromodomain containing 3                                                                    Brd3          2     TRA    27.94   16.66   3.39    4.77    2.01    14.14
  HL     Calcium-binding protein, intestinal                                                         Cai           6     SIG    27.75   17.16   3.28    4.32    1.43    11.94
  HL     Capicua homolog (*Drosophila*)                                                              Cic           7     TWC    16.98   27.73   3.50    0.64    1.93    25.56
  HL     Drebrin-like                                                                                Dbnl          11    CYT    17.11   27.81   3.65    2.36    2.36    5.61
  HL     Ferredoxin reductase                                                                        Fdxr          11    ENE    27.09   17.61   3.58    1.56    2.30    7.47
  HL     Fibroblast growth factor (acidic) intracellular-binding protein                             Fibp          19    CSD    17.16   27.91   3.50    2.78    2.07    6.41
  HL     FLN29 gene product                                                                          Fln29-pend    5     UNK    27.91   17.43   3.50    0.87    0.82    14.35
  HL     HECT domain containing 1                                                                    Hectd1        12    UNK    17.06   27.91   3.47    2.91    4.48    7.42
  HL     Inhibitor of kappaB kinase epsilon                                                          Ikbke         1     SIG    27.86   17.13   3.52    1.40    0.79    13.51
  HL     Myotubularin-related protein 1                                                              Mtmr1         X     CYT    27.97   17.19   3.39    5.46    1.48    8.10
  HL     Phosphatidylinositol-4-phosphate 5-kinase, type II, alpha                                   Pip5k2a       2     ENE    16.90   27.75   3.58    1.69    1.72    17.61
  HL     Procollagen C-endopeptidase enhancer 2                                                      Pcolce2       9     JAE    17.16   27.65   3.55    3.60    2.38    15.12
  HL     Protein tyrosine phosphatase, non-receptor type 9                                           Ptpn9         9     SIG    17.13   28.02   3.42    1.14    3.87    16.58
  HL     Pyruvate dehydrogenase kinase, isoenzyme 4                                                  Pdk4          6     ENE    27.81   17.21   3.44    2.89    0.85    9.06
  HL     von Hippel--Lindau-binding protein 1                                                        Vbp1          X     TWC    16.84   27.83   3.20    1.62    2.67    8.61
  LH     Abhydrolase domain containing 3                                                             Abhd3         18    ENE    0.95    1.93    18.88   17.21   23.86   3.20
  LH     Acetyl-coenzyme A acyltransferase 2 (mitochondrial 3-oxoacyl-coenzyme A thiolase)           Acaa2         18    ENE    1.35    1.30    25.32   17.64   23.57   3.76
  LH     ATP synthase, H+ transporting, mitochondrial F0 complex, subunit c (subunit 9), isoform 2   Atp5g2        15    TWC    1.22    1.62    19.92   17.29   24.02   3.47
  LH     Hematopoietically expressed homeobox                                                        Hhex          19    TRA    1.24    1.22    19.15   23.65   17.16   3.84
  LH     Immediate early response 3                                                                  Ier3          17    CSD    1.06    1.59    22.75   16.23   23.41   4.21
  LH     Interleukin-1 receptor-associated kinase 1                                                  Irak1         X     SIG    1.38    1.11    19.54   19.31   22.48   3.36
  LH     Polymerase (DNA directed), beta                                                             Polb          8     TRA    1.77    1.11    14.96   23.54   16.26   3.97
  LH     RAD9 homolog (*S. pombe*)                                                                   Rad9          19    CSD    1.88    0.95    21.35   23.15   18.86   3.05
  LH     Resistin like beta                                                                          Retnlb        16    UNK    1.69    1.19    16.39   21.74   19.20   3.50
  LH     Retinol-binding protein 4, plasma                                                           Rbp4          19    TWC    1.93    0.98    17.45   23.62   18.30   3.73
  LH     RME8 protein                                                                                Rme8-pend     9     UNK    1.59    1.11    22.80   16.92   23.09   3.23
  LH     Sorting nexin 10                                                                            Snx10         6     TWC    1.01    1.67    25.72   16.98   23.83   4.10
  LH     Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, beta polypeptide    Ywhab         2     TWC    1.48    1.22    12.00   19.17   22.25   3.36
  LH     UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 4          Galnt4        10    ENE    1.91    1.01    22.67   23.25   18.64   3.39
  LH     v-rel reticuloendotheliosis viral oncogene homolog A (avian)                                Rela          19    TRA    1.83    0.85    17.88   23.73   16.84   4.03
  LL     AE-binding protein 2                                                                        Aebp2         6     TRA    1.80    0.95    24.97   1.85    4.82    16.45
  LL     CDC26 subunit of anaphase promoting complex                                                 Cdc26-pen     4     CSD    1.80    1.03    12.66   3.81    2.15    13.72
  LL     COP9 (constitutive photomorphogenic) homolog, subunit 4 (*Arabidopsis thaliana*)            Cops4         5     TRA    1.09    1.59    22.62   3.34    2.94    10.62
  LL     Fc receptor, IgG, low affinity III                                                          Fcgr3         1     JAE    1.17    1.40    15.63   2.17    2.44    5.88
  LL     Glypican 1                                                                                  Gpc1          1     JAE    1.22    1.32    18.91   2.67    2.54    5.56
  LL     Hairy/enhancer-of-split related with YRPW motif-like                                        Heyl          4     TRA    1.93    0.93    24.21   0.82    0.74    16.34
  LL     Leucine-zipper-like transcriptional regulator, 1                                            Lztr1         16    TRA    1.77    1.14    20.31   2.17    2.44    4.13
  LL     Msx2 interacting nuclear target protein                                                     Mint-pendin   4     UNK    1.62    1.17    21.80   4.63    2.01    14.30
  LL     NADH dehydrogenase (ubiquinone) Fe-S protein 1                                              Ndufs1        1     ENE    1.30    1.24    15.52   2.15    1.40    12.50
  LL     Piwi like homolog 2 (*Drosophila*)                                                          Piwil2        14    CSD    1.30    1.24    24.76   2.73    0.90    6.41
  LL     Pre-B-cell leukemia transcription factor 3                                                  Pbx3          2     TRA    1.40    1.51    12.05   2.04    1.88    19.33
  LL     Solute carrier family 5 (sodium-dependent vitamin transporter), member 6                    Slc5a6        5     TIC    1.11    1.40    16.18   0.50    0.87    18.19
  LL     TBP-interacting protein                                                                     Tp120a-pe     10    TRA    1.69    1.24    9.38    2.04    2.41    18.03
  LL     von Hippel--Lindau syndrome homolog                                                         Vhlh          6     TWC    1.17    1.43    16.10   4.58    1.56    15.20
  LL     WD repeat domain 9                                                                          Wdr9          16    TRA    1.24    1.59    10.54   1.59    4.13    9.38

*H, high coordination; L, low coordination, first symbol in Type column indicating the coordination degree in the* **C** *and second one in the* **E** *extract; CHR, chromosome location; FUNC, primary function performed by the encoded protein; SYN, synergistic expression; ANT, antagonistic expression; IND, independent expression*.

Transcriptomic "see-saws"
-------------------------

We compared the coordination profiles of selected genes involved in immune response, myelination, and calcium signaling by computing their OVL. The rationale for selecting these genes was that EAE is a rodent immune-cell-mediated inflammatory demyelinating disease and that calcium signaling (Iacobas et al., [@B27]) is directly related to myelination (Butt, [@B10]; Fields, [@B20]). Although as expected, the coordination see-saws were exceptions, as most gene pairs exhibited neutral coordination profiles; in all functional categories, we identified genes with striking likeness or opposition, as illustrated for Pmp22 in Figure [5](#F5){ref-type="fig"} in controls. Figure [5](#F5){ref-type="fig"} illustrates also how the "see-saw" partnership (here of Pmp22) in control SC was altered by disease. Figure 5**See-saw partners of peripheral myelin protein (Pmp22) in control spinal cord and alteration by AT-EAE**. (***A*** and ***D***) Immune response partners. (***B*** and ***E***) Platelet derived growth factors. (***C*** and ***F***) Calcium signaling genes. The correlation coefficients of the indicated genes with each other gene were plotted against those of Pmp22 with each other gene. In controls, red color indicates likeness, green neutrality, and blue opposition. The table presents the overlap (OVL) of the coordination profiles in both conditions. Note that the AT-EAE turned the significant similarity and opposition of the coordination profiles into neutrality. Cklfsf3, chemokine-like factor super family 3; Ifitm3, interferon-induced transmembrane protein 3; Ier3, immediate early response 3; Pdgfra, platelet derived growth factor receptor, alpha polypeptide; Pdfrl, platelet-derived growth factor, receptor-like; Pdgfc, platelet-derived growth factor, C polypeptide; Itpr1, inositol 1,4,5-triphosphate receptor 1; Grinl1a, glutamate receptor, ionotropic, N-methyl D-aspartate-like 1A; P2rx3, purinergic receptor P2X, ligand-gated ion channel, 3. The overlap scores (OVL) of the Pmp22 in the two conditions were: PartnerCklfsf3Ifitm3Ier3PdgfraPdfrlPdgfcItpr1Grinl1aP2rx3Control98.51−93.57−4.5693.23−81.123.9492.30−95.59−0.86AT-EAE15.5421.4416.34−12.172.72−15.15−6.0937.860.50

Table [7](#T7){ref-type="table"} lists the most strikingly similar or opposite see-saw partners within genes responsible for myelination, calcium signaling, and immune response. The pair H2-DMa: Psmb9 (histocompatibility 2, class II, locus DMa: proteosome (prosome, macropain) subunit, beta type 9 (large multifunctional protease 2)) has the highest likeness, while the pair Scd2:Plcl2 (stearoyl-coenzyme A desaturase 2: phospholipase C-like 2) has the highest opposition as coordination profiles. Pmp22 shared with Pdgfra 956 of its 1039 synergistic partners and 561 of its 593 antagonistic partners, and with Itpr1 929 synergistic and 522 antagonistic partners. In addition, 667 synergistic partners of Pmp22 are antagonistic for Pdgfrl and 979 are antagonistic for Grinl1a, while 442 antagonistic partners of Pmp22 are synergistic for Pdgfrl and 557 are synergistic for Grinl1a. The values of the OVL in legend of Figure [5](#F5){ref-type="fig"} confirmed the higher similarity and opposition of the coordination profiles of the illustrated genes.

###### 

**The most like (OVL \> 90) and opposite (OVL \< −90) see-saw partners among genes involved in myelination (MYE), calcium signaling (CAS), and immune response (IRS) in spinal cord of adult control female mice**.

  Pair             OVL     Pair             OVL      Symbol    Name
  ---------------- ------- ---------------- -------- --------- -----------------------------------------------------------------------------------------
  H2-DMa:Psmb9     99.45   Scd2:Plcl2       −99.84   Bcap31    B-cell receptor-associated protein 31
  Pdgfra:Pdia4     99.17   H2-Eb1:Ifitm3    −97.48   Bcl2a1b   B-cell leukemia/lymphoma 2-related protein A1b
  Pmp22:Cmtm3      98.52   Pmp22:Grinl1a    −95.59   Bmi1      B lymphoma Mo-MLV insertion region 1
  Plp:Fyn          97.60   Cd1d1:H13        −94.84   C1qb      Complement component 1, q subcomponent, beta polypeptide
  Bmi1:Cd1d1       97.34   Pdgfra:Grinl1a   −94.70   Cab39     Calcium-binding protein 39
  Cd44:Cd300d      97.14   Ifitm1:Oasl2     −94.44   Capns1    Calpain, small subunit 1
  H2-Ab1:Lrba      96.84   Mal:Tuba8        −94.25   Ccl11     Small chemokine (C--C motif) ligand 11
  Pdgfrl:Mal       96.22   Cmtm3:Ifitm3     −94.20   Cd1d1     CD1d1 antigen
  Pdgfrb:Cab39     96.19   Bmi1:H13         −93.79   Cd300d    Cd300D antigen
  Pdgfrb:H2-Aa     95.44   Pmp22:Ifitm3     −93.57   Cd44      CD44 antigen
  Cmtm3:H2:Eb1     95.10   C1qb:H2-Ab1      −93.47   Cherp     Calcium homeostasis endoplasmic reticulum protein
  Bcap31:Ifitm3    94.93   C1qb:Lrba        −93.42   Cmtm3     CKLF-like MARVEL transmembrane domain containing 3
  Il2rg:Psmb9      94.78   Bcap31:H2-Eb1    −92.57   Fyn       Fyn proto-oncogene
  Pmp22:S100a6     94.67   Pdgfra:Plcd1     −92.04   Grinl1a   Glutamate receptor, ionotropic, N-methyl [D]{.smallcaps}-aspartate-like 1A
  H2-Dma:Il2rg     94.44   Cd44:H13         −92.01   H13       Histocompatibility 13
  Pmp22:H2:Eb1     94.01   Bcl2a1b:Irf6     −91.93   H2-Aa     Histocompatibility 2, class II antigen A, alpha
  Pmp22:Pdia4      93.90   Pdgfrl:S100g     −91.91   H2-Ab1    Histocompatibility 2, class II antigen A, beta 1
  Scd2:Snx9        93.85   Ccl11:Psmb8      −91.89   H2-DMa    Histocompatibility 2, class II, locus DMa
  Mpz:Hmgcr        93.82   Pdgfrl:Tuba8     −91.79   H2-Eb1    Histocompatibility 2, class II antigen E beta
  Pdgfrb:H2-L      93.70   Scd2:Tuba8       −91.78   H2-K1     Histocompatibility 2, K1, K region
  Mal:Qk           93.49   Pmp22:Hspb1      −91.34   H2-L      Histocompatibility 2, L region
  Pmp22:Capn3      93.37   Pdgfra:Hspb1     −90.96   H2-Q7     Histocompatibility 2, Q region locus 7
  Irf6:Lrba        93.34   Bcap31:Psmb8     −90.51   Hmgcr     3-Hydroxy-3-methylglutaryl-coenzyme A reductase
  Pdgfrl:Qk        93.28   Bcap31:Cmtm3     −90.23   Hspb1     Heat shock protein 1
  Pmp22:Pdgfra     93.23   Bcap31:Pmp22     −90.16   Ifitm1    Interferon-induced transmembrane protein 1
  Pdgfra:S100a6    93.19   H13:Cd300d       −90.02   Ifitm3    Interferon-induced transmembrane protein 3
  Pdgfra:Itpr1     92.66                             Ifitm3l   Interferon-induced transmembrane protein 3-like
  Pdgfrb:Camk2g    92.49                             Il2rg     Interleukin 2 receptor, gamma chain
  Mal:Snx9         92.39                             Irf6      Interferon regulatory factor 6
  Pmp22:Itpr1      92.30                             Itpr1     Inositol 1,4,5-triphosphate receptor 1
  Pdgfrb:Fyn       92.06                             Lrba      LPS-responsive beige-like anchor
  Pmp22:Capns1     91.58                             Mal       Myelin and lymphocyte protein, T-cell differentiation protein
  Pdgfra:Capns1    91.54                             Mpz       Myelin protein zero
  Pmp22:Pde4a      91.54                             Oasl2     2′-5′-Oligoadenylate synthetase-like 2
  Pdgfra:Plcg2     91.43                             Pdgfra    Platelet-derived growth factor receptor, alpha polypeptide
  H2:Ab1:Irf6      91.32                             Pdgfrb    Platelet-derived growth factor receptor, beta polypeptide
  Pdgfra:Capn3     91.31                             Pdgfrl    Platelet-derived growth factor receptor-like
  Plp:Cab39        90.92                             Pdia4     Protein disulfide isomerase-associated 4
  Pdgfrl:Snx9      90.90                             Plcd1     Phospholipase C, delta 1
  Scd2:Cherp       90.66                             Plcl2     Phospholipase C-like 2
  H2-Aa:H2-L       90.47                             Plp       Proteolipid protein (myelin)
  Pdgfrl:Cd44      90.45                             Pmp22     Peripheral myelin protein
  Pdgfrl:S100a11   90.35                             Psmb8     Proteosome (prosome, macropain) subunit, beta type 8 (large multifunctional protease 7)
  Bcl2a1b:Cd1d1    90.33                             Psmb9     Proteosome (prosome, macropain) subunit, beta type 9 (large multifunctional protease 2)
  Bcl2a1b:Bmi1     90.32                             Qk        Quaking
  Plp-H2-Aa        90.30                             S100a11   S100 calcium-binding protein A11 (calizzarin)
  H2:K1:H2:Q7      90.16                             S100a6    S100 calcium-binding protein A6 (calcyclin)
  H2-Ab1-Tnfaip2   90.06                             S100g     S100 calcium-binding protein G
  Pdgfrb:Plp       90.05                             Scd2      Stearoyl-coenzyme A desaturase 2
                                                     Snx9      Sorting nexin 9
                                                     Tnfaip2   Tumor necrosis factor, alpha-induced protein 2
                                                     Tuba8     Tubulin, alpha 8

Discussion
==========

Confirmation of array data
--------------------------

Our microarray data are in surprisingly high qualitative agreement with those previously obtained by another group on SC of spontaneous EAE mice through the use of Affymetrix arrays (where some regulations were confirmed by qRT-PCR; Matejuk et al., [@B38]). As illustrated in Table [8](#T8){ref-type="table"}, when common hits were compared between data sets, only 2 of 40 genes (granulin and mevalonate diphospho decarboxylase) showed opposite regulation. Even though magnitudes of expression changes varied between these studies, this qualitative OVL is remarkable, given reports of poor correlations between results provided by different microarray platforms even for the same extracts (e.g., Knudtson et al., [@B33]).

###### 

**Common hits for EAE spinal cord in this study and that by Matejuk et al., (13) obtained through Affymetrix (Affy) and qRT-PCR (QPCR) techniques**.

  Name                                                                     Symbol       cDNA        *p*-Value   Affy       p-Value     QPCR
  ------------------------------------------------------------------------ ------------ ----------- ----------- ---------- ----------- -------
  Beta-2 microglobulin                                                     B2m          5.59        0.001       10.8       0.010       
  Cathepsin C                                                              Ctsc         4.14        0.001       21.1       0.000       12.0
  Cathepsin S                                                              Ctss         14.23       0.000       8.3        0.000       
  Cathepsin Z                                                              Ctsz         5.93        0.000       8.2        0.000       
  CCAAT/enhancer-binding protein (C/EBP), beta                             Cebpb        1.32        0.119       4.6        0.010       
  CD44 antigen                                                             Cd44         3.24        0.000       6.2        0.020       
  CD53 antigen                                                             Cd53         1.54        0.404       10.9       0.020       
  Ceruloplasmin                                                            Cp           4.33        0.012       4.6        0.010       
  Complement component 1, q subcomponent, alpha polypeptide                C1qa         10.03       0.000       12.2       0.000       
  Complement component 1, q subcomponent, beta polypeptide                 C1qb         8.45        0.000       9.9        0.000       
  Complement component 3                                                   C3           4.33        0.005       11.4       0.000       8.0
  Cysteine-rich protein 1 (intestinal)                                     Crip1        2.39        0.001       8.8        0.030       
  EGF-like module containing, mucin-like, hormone receptor-like sequence   Emr1         2.85        0.001       6.3        0.010       
  Fc receptor, IgG, high affinity I                                        Fcgr1        1.20        0.388       5.6        0.010       5.0
  **Granulin**                                                             **Grn**      **−2.47**   **0.003**   **4.1**    **0.000**   
  GTP-binding protein 4                                                    Gtpbp4       2.01        0.004       135.8      0.000       
  Histocompatibility 2, class II antigen A, alpha                          H2-Aa        26.37       0.000       424.2      0.000       124.6
  Histocompatibility 2, class II antigen A, beta 1                         H2-Ab1       6.67        0.000       76.0       0.000       
  Histocompatibility 2, class II antigen E beta                            H2-Eb1       1.78        0.042       66.1       0.000       
  Histocompatibility 2, D region locus 1                                   H2-D1        5.30        0.001       15.8       0.000       
  Histocompatibility 2, K region                                           H2-K         6.33        0.000       14.4       0.000       
  Histocompatibility 2, Q region locus 7                                   H2-Q7        2.44        0.004       19.7       0.000       
  Ia-associated invariant chain                                            Ii           1.76        0.023       81.1       0.000       
  Inositol polyphosphate-5-phosphatase B                                   Inpp5b       2.74        0.000       15.0       0.000       
  Interferon activated gene 203                                            Ifi203       2.79        0.001       4.6        0.020       
  Interferon consensus sequence-binding protein 1                          Icsbp1       3.01        0.000       6.8        0.000       
  Interferon regulatory factor 1                                           Irf1         3.04        0.000       10.3       0.000       
  Lymphocyte specific 1                                                    Lsp1         1.86        0.022       9.2        0.000       
  Lysosomal-associated protein transmembrane 5                             Laptm5       5.49        0.001       5.7        0.000       
  **Mevalonate (diphospho) decarboxylase**                                 **Mvd**      **1.76**    **0.001**   **−5.4**   **0.000**   
  mutS homolog 3 (*E. coli*)                                               Msh3         2.11        0.001       5.1        0.010       
  Proteasome (prosome, macropain) 28 subunit, alpha                        Psme1        2.27        0.003       6.3        0.000       
  SAM domain and HD domain, 1                                              Samhd1       3.04        0.000       6.8        0.030       
  Signal transducer and activator of transcription 1                       Stat1        6.09        0.000       15.2       0.010       8.0
  Signal transducer and activator of transcription 6                       Stat6        4.15        0.000       15.8       0.000       
  Suppressor of cytokine signaling 3                                       Socs3        1.43        0.017       26.3       0.030       
  T-cell receptor alpha, variable 22.1                                     Tcra-V22.1   3.51        0.000       6.0        0.030       
  Tumor necrosis factor, alpha-induced protein 2                           Tnfaip2      3.53        0.000       5.0        0.020       
  TYRO protein tyrosine kinase-binding protein                             Tyrobp       2.80        0.000       7.9        0.000       
  Vesicle-associated membrane protein 8                                    Vamp8        3.21        0.001       5.8        0.000       

*Note that all 40 but 2 (enhanced) genes were found to be regulated in the same sense by both cDNA microarray and Affymetrix studies; exceptions are given in bold. The fold changes obtained by the two platforms was very similar in the case of Laptm5 (98%), Cp (97%), C1qb (92%) and C1qa (90%). Five common hits were also confirmed by Matejuk et al., [@B38] through qRT-PCR*.

Connexin43 is a key gene of the SC transcriptome
------------------------------------------------

The remarkable OVL between the regulomes of AT-EAE SC and Cx43 null brain indicates that in pathological conditions in which Cx43 is regulated a subset of the altered transcriptome may be attributable to the alteration in Cx43. This finding provides additional support for the hypothesis that Cx43 is a node of gene expression regulation, where its expression is closely tied to that of many other genes (Iacobas et al., [@B28]; Iacobas et al., [@B29]; Spray and Iacobas, [@B48]). Although mechanisms responsible for the regulation of other genes by Cx43 expression remain to be completely understood, they likely include regulation of signal molecule exchange between coupled cells and binding to Cx43 cytoplasmic domains of molecules with TRA factor activity (see Kardami et al., [@B32]).

Gene cohorts were perturbed but not regulated
---------------------------------------------

Cohort analysis of quantified genes has the advantage of providing both manageable and statistically significant ontological information. The expression analysis of gene cohorts is significantly more accurate than that of individual genes due to averaging of technical noise in expression levels of individual genes. In addition, it provides a measure of tendency toward particular patterns of expression. Although we found that no gene cohort was significantly regulated in AT-EAE SC with respect to control (due to a rough balance between up- and down-regulation of individual genes), all cohorts were significantly perturbed, meaning that the disease significantly altered the proportions of transcript abundances within each cohort. Presumably, these "stoichiometric" perturbations contribute to phenotypic alterations that lead to neurological impairment in AT-EAE, including the inflammation, demyelination, axonal damage, and cell death that are associated with infiltration of myelin-specific inflammatory Th1 CD4^+^ T-cells and, subsequently, activated monocytes into the CNS (Ercolini and Miller, [@B18]). Interestingly, the highest perturbation was that of JAE genes and chromosome 17 due to the up-regulation of all nine histocompatibility 2 genes involved in immune defense response that were quantified (H2-Aa, H2-Ab1, H2-Eb1, H2-Dma, H2-Bf, H2-D1, H2-K, H2-L, H2-Q7), consistent with the inflammatory nature of the disease. Remarkably, mouse chromosome 17 has the largest homology with human chromosome 6p21, the locus containing the major histocompatibility complex known to influence susceptibility to MS (Yeo et al., [@B52]).

AT-EAE SC has a loose control of gene expression
------------------------------------------------

Since AT-EAE represents a massive immunological response resulting in gross tissue changes, we examined whether this condition altered the overall inter-animal gene expression variability as compared to healthy mice, expecting that AT-EAE mice would have greater variability due to differences in disease status or in immune attack. Indeed, although for 44.3% of the studied genes the TRA variability decreased, the overall REV value increased from 42.5% in the control mice to 49.7% in the AT-EAE mice, indicating a significant (*p* \< 0.0001) loss of the overall TRA control in the diseased mice. In addition, the sets of REV values in the two conditions were independent (ρ \< 10^−23^) suggesting that multiple mechanisms may contribute to alter the TRA control stringency of individual genes.

Among the most stably expressed genes in control SC whose expression was not affected by AT-EAE was cadherin 2 (Cdh2), which is required for regulating presynaptic function at glutamatergic synapses (Jungling et al., [@B31]). In contrast, interleukin-1 receptor-associated kinase 1 (Irak1), critical for the induction of EAE as well as for the activation and expansion of autoreactive T-cells (Deng et al., [@B14]), was very stably expressed in control but became very unstably expressed in AT-EAE, in line with the dynamic nature of the inflammatory process in the disease.

AT-EAE remodels the expression coordination network in SC
---------------------------------------------------------

The coordination analysis revealed complex interlinkages of gene expression in both control and AT-EAE SC and that the pathology not only alters expression of individual genes but also perturbs functional pathways and rearranges transcriptomic interlinkages However, AT-EAE did not change significantly the average extents of the synergomes, antagomes, and exclusomes, in contradiction with what we have observed in Cx43 null brain were the expressome sizes diminished by more than 20% with respect to the wildtype brain (Iacobas et al., [@B28]).

Adam10, the disintegrin and metalloprotease that modulates the cell adhesion role of Pcdh gamma (Reiss et al., [@B43]) displayed the largest synergome (28.0%), while spastic paraplegia 7 homolog (Spg7), encoding a protein involved in anterograde axon cargo transport (Ferreirinha et al., [@B19]), had the largest antagome (28%). Remarkably, peripheral myelin protein (Pmp22) was found to be the most coordinately expressed gene involved in myelination (43.2%), while neutral sphingomyelinase activation-associated factor (Nsmaf) was found to be the least coordinated (5.0%). The very large expressome of Pmp22 is consistent with its role in mediating the interaction of Schwann cells with the extracellular environment (Amici et al., [@B3]; Amici et al., [@B4]; Berger et al., [@B7]) and the consequences of its misexpression in generating a family of hereditary peripheral neuropathies (Amici et al., [@B4]; Sereda and Nave, [@B46]).

Among the genes responsible for the immune response, interferon-induced transmembrane protein 3 (Ifitm3), involved in the negative regulation of cell proliferation (Ropolo et al., [@B44]), had the largest expressome (44.4%) and Fc receptor IgG low affinity III (Fcgr3) the smallest (2.5%). Ifitm3 also displayed the largest antagome (27.8%), while histocompatibility 2 class II antigen E beta (H2-Eb1), involved in antigen processing via MHC class II (Alfonso et al., [@B2]), had the largest synergome (27.5%). Immediate early response 3 (Ier3) appeared to have the largest exclusome (11.2%). Complex gene--gene interactions within the inflammatory pathway have also been reported by other groups. For example, Motsinger et al., [@B40] explored 51 single nucleotide polymorphisms (SNPs) in 36 candidate genes within the inflammatory pathway, finding that multi-locus models successfully predicted MS disease risk with high accuracy.

The bimodal distributions of the expressome sizes of SC in both control and disease (Figure [3](#F3){ref-type="fig"}B), was more prominent than that found in the brain (Iacobas et al., [@B25]), and suggest the existence of two categories of genes in terms of coordinations with other genes.

The perspective of "see-saw" partnership
----------------------------------------

The redundancy provided by similar or opposite coordination profiles may offer the possibility to compensate for functional effects of alteration in gene expression through regulation of interlinked partners. The striking similarity or opposition with regard to coordination profile of Pmp22 with genes such as Pdgfra and Pdgfrl (Figure [5](#F5){ref-type="fig"}B) may explain why some of the Pdgf genes have been reported to act individually and/or cooperatively in spontaneous remyelination (Murtie et al., [@B41]). A particularly interesting result of our study was the finding of strikingly similar or opposite partners of Pmp22 in the immune response gene cohort (Cklfsf3 and Ifitm3, Figure [5](#F5){ref-type="fig"}A), intercellular calcium signaling (inositol 1,4,5-triphosphate receptor 1 (Itpr1) and glutamate receptor ionotropic N-methyl [D]{.smallcaps}-aspartate-like 1A (Grinl1a)) (Figure [5](#F5){ref-type="fig"}C). Itpr1 is responsible for calcium mobilization from the endoplasmic reticulum calcium stores (Iacobas et al., [@B27]), while Grinl1a allows calcium ions from the extracellular space to diffuse into the cell when activated by glutamate. The existence of these "see-saw" partners of myelination genes suggests the possibility of correcting myelin defects through stimulating or inhibiting genes responsible for calcium signaling and immune response due to their similar or opposite interlinkage with thousands of genes. These relations between the coordination profiles can be substantially altered in pathological conditions as presented in Figures [5D--5F](#F5){ref-type="fig"}. These findings of network alterations add a novel concept to expression analysis, in which gene expression profiles can be considered not only by whether expression of genes in a similar functional pathway are affected, but also with regard to how their linkage to one another is altered in a disease state.

We have previously reported (Brand-Schieber et al., [@B8]) that the gene encoding the gap junction protein Cx43, the most abundant connexin expressed in astrocytes, was among the down-regulated genes in AT-EAE, a result recently confirmed in a guinea pig model of EAE (Roscoe et al., [@B45]). We concluded that in addition to damage of myelinating glia, altered astrocyte connectivity is a prominent feature of inflammatory demyelination. In order to test the hypothesis that coordinated expression with Cx43 might account for some of the observed altered patterns of gene expression, we have compared the coordination profile of Gja1 to those of the immune response and myelination genes quantified in this experiment. Thus, the coordination profile of Gja1 had a remarkable likeness with those of: histocompatibility 2 Q region locus 7 (H2-Q7, OVL = 87.4%), Psmb9 (OVL = 84.8%), H2-DMa (OVL = 84.5%), interleukin 2 receptor gamma chain (Il2rg, OVL = 83.6%), myelin protein zero (Mpz, OVL = 82.4%), complement component 1 q subcomponent beta polypeptide (C1qb, OVL = 81.6%), and proteolipid protein (myelin) (Plp, OVL = 75.5%). These associations may suggest that the consequences of altered Cx43 expression in damaged SC, evoked by endogenous mechanisms after traumatic SCI (Theriault et al., [@B50]) might be compensated by overexpression of these other genes. In this regard, we particularly highlight the myelination genes Mpz and Plp because of the prevalence of white matter disturbance in oculodentodigital dysplasia syndrome (Loddenkemper et al., [@B37]), which is caused by dysfunctional Cx43 mutations (Shibayama et al., [@B47]). As a corollary of this hypothesis, we might predict that pro-myelinating treatments would result in increased Cx43 expression in SC. Such a result has been recently reported as a consequence of treatment with two drugs in a guinea pig model of EAE (Roscoe et al., [@B45]).

Conclusion
==========

We found that AT-EAE had a strong impact on the transcriptomic organization of the SC, perturbing most of the functional pathways, relaxing the TRA control, and altering the expression coordination of numerous genes, including those involved in myelination, immune response, and calcium signaling. In addition, identification of what we termed "see-saw" partners may provide alternative therapeutic targets for specific gene-related diseases.
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